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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1)
treatment has made significant progress with the
success of highly active antiretroviral therapy
(HAART) using protease inhibitors and reverse tran-
scriptase inhibitors. However, long-term use of
HAART is currently limited by developed resistance
(1-4) and toxicities (5, 6) associated with many of
these treatments. New antiretroviral drugs with
novel mechanisms of action and/or distinct HIV-1
resistance profiles are thus required to continue ef-
fective HAART for the treatment of HIV-1.
Maraviroc is one of a new class of antiretroviral
compounds known as CCR5 antagonists. Maraviroc
prevents HIV-1 from entering CCR5+ CD4+ cells by
acting as an antagonist at the CCR5 coreceptor (7-
10). This drug in combination with other antiretrovi-
ral drugs has been demonstrated to be useful for
treating therapy-experienced and -naïve patients
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infected with CCR5 tropic HIV-1 (11, 12).
On the other hand, drug interaction studies show
changes in maraviroc exposure when administered
with other anti-HIV medications, including efavirenz
and protease inhibitors (13, 14). These changes re-
quire alterations in the doses of maraviroc to use.
Therefore, monitoring plasma maraviroc concentra-
tions is essential.
Fayet et al. (15) and Martin et al. (16) have re-
cently determined plasma maraviroc concentrations
using liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). The LC-MS/MS assay is
very sensitive and accurate, but these methods have
several disadvantages in terms of cost performance
and essential equipment. Notari et al. (17) also re-
ported a determination method using HPLC-UV.
However, HPLC method has some complicated pro-
cedures, such as the solid-phase drug extraction.
In addition, according to our preliminary HPLC ap-
plication, the sensitivity of LC-MS methods must
at least be determined for clarification of measure-
ments. To bypass these difficulties, we aimed to
develop more conventional procedures for deter-
mining maraviroc using LC-MS. The principal ad-
vantages of our method are rapid liquid-liquid drug




Maraviroc was supplied by Pfizer (New York,
NY, USA) and the internal standard (IS), A-86093
(5S,8S,10S,11S)-9-hydroxy-2-cyclopropyl-5-(1-
methylethyl)-1-[(2-1-methylethyl)-4-thiazolyl]-3,6-
dioxo-8,11-bis ( phenylmethyl )-2,4,7,12- tetraaza-
tridecan-13-oic acid, 5-thiazolylmethyl ester, was
provided by Abbott Laboratories (Abbott Park, IL,
USA). Their chemical structures are shown in
Figure 1. Methanol, hexane, methylene chloride and
acetonitrile (Kanto Chemical, Tokyo, Japan) were of
HPLC grade. Ammonium acetate, EDTA and ace-
tic acid were purchased from Katayama Chemical
(Osaka, Japan). Water was deionized and osmosed
using a Milli-Q system (Millipore, Bedford, MA,
USA). All other chemicals and solvents were of ana-
lytical grade.
Equipment
A Waters Alliance 2695 HPLC system and a
Micromass ZQ-2000 MS system (Waters, Milford,
MA, USA), controlled with MassLynx version 4.0
software (Waters), were used for detection. The ana-
lytical column was a SunFire C18 column (3.5 μm,
2.150 mm ; Waters), protected by a SunFire C18
Guard column.
Chromatographic and Mass Spectrometric Condi-
tions
The mobile phase was a mixture of 0.1 mM
EDTA in 0.1% acetic acid (A), 100% acetonitrile (B)
and 100% methanol (C). An isocratic mobile phase
consisting of A-B-C (87 : 8 : 5) was used during the
first 2 min of the run, followed by a linear gradient
elution consisting of A-B-C (15 : 80 : 5) for the next
8 min. The final conditions (15 : 80 : 5) were main-
tained for the final 5 min. The system was then re-
equilibrated for an additional 25 min using the in-
itial conditions. The flow rate of the mobile phase
was 0.2 ml/min, column temperature was 40, and
the amount of injected sample was 5 μl.
The mass spectrometer was operated in positive
ion electrospray mode. Capillary sprayer voltage was
3.5 kV and sample cone voltage was 30 V for both
maraviroc and A-86093. The source temperature
was 120and the desolvation temperature was
350. The desolvation and cone gas flow rates were
set to 600 and 50 L/h, respectively. The acquisition
mass range was m/z 200-800 at 0.5 s/scan with a
0.1-s interscan delay. All mass spectra were ac-
quired in centroid mode.
Fig. 1. Chemical structures of maraviroc and the internal standard A-86093.
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Quantitative analysis, performed in selected-ion
recording (SIR) mode, detected maraviroc at m/z
514.7, and the IS (A-86093) at m/z 748.0, all in the
form of ions. Quantitation calculations were per-
formed using MassLynx version 4.0 analytical soft-
ware.
Standard Solutions
Stock solutions of maraviroc and A-86093 were
prepared by dissolving accurately weighed amounts
of each reference compound in water/ethanol (50 :
50, v/v) to yield concentrations of 87.5 μg/ml ma-
raviroc and 41.0 μg/ml A-86093. These stock solu-
tions were stored at -80and thawed on the day
of analysis. The stock solution was diluted in drug-
free plasma to yield maraviroc concentrations of
0.011, 0.109, 0.438, 1.094 and 2.188 μg/ml.
Sample Preparation
A 2-ml aliquot of methylene chloride/hexane
(50 : 50, v/v) containing the IS (0.164 μg/ml) and
0.3 ml of 0.2 M ammonium acetate were added to
500 μl plasma sample prepared from peripheral blood
anticoagulated with heparin. The mixture was vor-
texed for 5 min and then centrifuged at 3500g for 5
min. The upper layer was separated and evaporated
dry. This dried material was then dissolved in 50 μl
mobile phase solution. Lastly, 5 μl upper solution was
injected into the LC-MS system. The institutional
review board of National Hospital Organization
Nagoya Medical Center approved this study and
each subject provided written informed consent.
Validation
Inter- and intraday precision values using this
method were estimated by assaying control plasma
containing 5 different concentrations of maraviroc
5 times on the same day and on 3 separate days to
obtain the relative standard deviation (RSD). Accu-
racy was determined as a percentage of the nomi-
nal concentration. To assess absolute recovery of
maraviroc extracted from plasma, peak area ratios
of analytes to IS were compared with those ob-
tained from the mobile phase with the same con-




Figures 2A and 2B show selected-ion recording
chromatograms obtained from a spiked plasma sam-
ple containing 0.875 μg/ml maraviroc and 0.164 μg/
Fig. 2. Selected- ion recording chromatograms for maraviroc and A-86093.
(A,B) Spiked plasma containing 0.875 μg/ml of maraviroc monitored with m/z 514.7 (A) and 0.164 μg/ml of A-86093 (IS) monitored
with m/z 748.0 (B).
(C,D) A blank plasma sample monitored with m/z 514.7 (C) and m/z 748.0 (D).
(C) and (D) are the expanded figures of the baselines in (A) and (B), respectively.
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ml A-86093 (IS). Under the described chroma-
tographic conditions, retention times were 8.00 min
for maraviroc and 13.6 min for A-86093. Figures
2C and 2D show chromatograms obtained from a
blank plasma sample. Assays performed on drug-
free human plasma successfully showed no inter-
fering peaks during the examined intervals of reten-
tion times. Figure 2D represents an expanded figure
of the baseline part of Figure 2B. These peaks did
not affect the quantification of IS. Anticoagulants
heparin and EDTA did not hinder the selected-ion
recording chromatograms for maraviroc and IS.
Validation : Linearity, Precision, Accuracy and Re-
covery
Calibration curves of maraviroc appeared linear
in the concentration range of 0.011-2.188 μg/ml,
with a correlation of 1.000.
The precision, accuracy, and recovery of our LC-
MS method are shown in Table 1. The selected
concentration of maraviroc covers the expected
plasma concentrations found in patients. RSDs cal-
culated for maraviroc in inter- and intraday assays
ranged from 3.2% to 7.1%, accuracy from 92.7% to
99.7% and recovery from plasma from 86.7% to
89.0%. Mean extraction recovery of IS was 87.9%.
These results indicate that this method achieves a
high degree of reproducibility and accuracy.
Clinical application
Figures 3 and 4 show chromatograms of a plasma
sample obtained from an HIV-1 infected patient on
Fig. 3. Selected- ion recording chromatograms of a plasma
sample obtained from patient 1.
Table 1. Intra- and interday precision and accuracy for maraviroc















0.011 0.0100.001 7.1 0.0100.001 5.5 92.75.1 86.74.2
0.109 0.1060.007 6.4 0.1050.007 6.8 96.26.6 88.92.9
0.438 0.4370.024 5.5 0.4230.022 5.1 96.64.9 89.04.4
1.094 1.0960.048 4.4 1.0910.051 4.6 99.74.6 87.64.3
2.188 2.1640.070 3.2 2.1220.081 3.8 96.53.7 87.64.6
RSD, relative standard deviation. Values indicate meanSD.
Fig. 4. Selected- ion recording chromatograms of a plasma
sample obtained from patient 2.
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maraviroc.
The patient 1 was a Japanese man aged 43 years
with a body weight of 38.0 kg. He had been treated
with maraviroc, lamivudine, etravirine, darunavir and
ritonavir for one month. Maraviroc was administered
at 150 mg once daily, because a strong CYP3A4
inhibitor, darunavir, was coadministered with ma-
raviroc. However, his CD4+ count was still 20/μl
with a viral load of 100,000 copies/ml. Successful vi-
rological treatment was not achieved. The maravi-
roc plasma concentration, measured at trough, was
0.024 μg/ml. In the DHHS guidelines (18), the sug-
gested minimum target trough maraviroc concen-
tration is more than 0.050 μg/ml. This treatment
failure may have been due to a low maraviroc trough
level and thus to elevate the trough level, we pro-
posed increasing the maraviroc dose to 300 mg
twice daily.
The patient 2 was a Japanese man aged 34 with
a body weight of 75.4 kg. He had been treated with
maraviroc, lamivudine, efavirenz, enfuvirtide, ti-
pranavir and ritonavir for two weeks. Maraviroc
was administered at 600 mg twice daily, because a
strong CYP3A4 inducer, efavirenz, was coadminis-
tered with maraviroc. At the start of this regimen, his
CD4+ count was 23/μl with a viral load of 220,000
copies/ml. After two weeks, his CD4+ count was
69/μl with a viral load of 3,500 copies/ml. The ma-
raviroc trough plasma concentration was 0.177 and
0.133 μg/ml. In this case, the maraviroc trough
levels were more than 0.050 μg/ml. The viral load
has been decreasing and treatment success is ex-
pected in the future. We thus proposed maintain-
ing the current daily dose of maraviroc.
DISCUSSION
Clinical trials of maraviroc have demonstrated po-
tent antiviral responses in patients infected with
CCR5 tropic HIV-1 who had previously received tri-
ple classes of antiretroviral drugs and/or were iden-
tified as triple-class resistant (19). Moreover, ma-
raviroc has demonstrated a clean safety profile in
these studies and may not have the toxicities and
tolerability issues seen with current anti-HIV drugs.
Maraviroc has thus become an important compo-
nent of combination treatment regimens for therapy-
experienced patients infected with CCR5 tropic
HIV-1.
Maraviroc is a substrate of CYP3A4 and Pgp, and
its pharmacokinetics is likely to be modulated by
inhibitors and inducers of these enzymes/transport-
ers (13, 14). Therefore, a dose adjustment is re-
quired when maraviroc is coadministered with those
drugs. To manage these drug interactions and en-
sure optimal drug efficacy, monitoring plasma ma-
raviroc concentrations is essential. For this purpose,
we developed a method for determining plasma ma-
raviroc concentrations using LC-MS. The maraviroc
calibration curve was linear within the concentration
range of 0.011 to 2.188 μg/ml, and average accu-
racy ranged from 92.7% to 99.7%. Both inter- and
intraday RSDs for maraviroc were less than 7.1%.
Recovery of maraviroc ranged from 86.7% to 89.0%.
Thus, our newly developed method achieved a high
degree of reproducibility and accuracy. In addition,
as plasma concentrations of maraviroc are report-
edly within 0.03-0.89 μg/ml when maraviroc is ad-
ministered at 300 mg twice daily (13), our method
successfully covers this region with good precision
and accuracy.
Our LC-MS method provides a conventional, ac-
curate and precise way to determine the maraviroc
concentration in human plasma. This method en-
ables a dose adjustment based on monitoring plasma
maraviroc concentrations for HIV-1-infected patients
and permits management of drug interactions and
toxicity.
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